EGFR and glioblastoma: Nimotuzumab, an mAb that targets the extracellular domain of EGFR, was tested in a phase II, single-arm, multicenter clinical trial (NCT03388372, https://clinicaltrials.gov/study/NCT03388372, accessed on 27 October 2024) to evaluate the benefit of adding it to standard therapy, and the results showed increased survival in newly diagnosed glioblastoma patients with positive EGFR expression [131].